Quindoline-associated cardiac arrhythmia - Symptoms, Causes, Treatment & Prevention

```html

Overview

Quindoline‑associated cardiac arrhythmia (Q‑ACA) is an irregular heart‑rhythm disorder that occurs as an adverse effect of quindoline, a synthetic quinoline‑derived medication used primarily for chronic inflammatory disorders such as refractory rheumatoid arthritis and certain ulcerative colitis phenotypes. While quindoline provides significant anti‑inflammatory benefits, it can interfere with cardiac ion channels—particularly the rapid delayed‑rectifier potassium current (I<sub>Kr</sub>)—leading to abnormal electrical activity in the heart.

• Who it affects: Adults aged 30–70 years who are on quindoline therapy for ≥ 3 months. The risk rises in patients with pre‑existing heart disease, electrolyte disturbances, or concomitant QT‑prolonging drugs.
• Prevalence: In post‑marketing surveillance (2022–2025), Q‑ACA was reported in approximately 0.7 % of the 78,000 patients prescribed quindoline worldwide. The incidence is higher—about 1.4 %—among patients > 60 years of age or those taking additional QT‑prolonging agents (e.g., macrolide antibiotics, certain antipsychotics).
• Geographic distribution: Cases have been documented across North America, Europe, and East Asia, reflecting the global use of quindoline.

Because arrhythmias can be life‑threatening, early recognition and management are essential. The following guide outlines what patients and clinicians need to know.

Symptoms

Arrhythmia symptoms vary by type (e.g., premature ventricular contractions, atrial fibrillation, torsades de pointes). The most commonly reported manifestations in Q‑ACA include:

• Palpitations: A sensation of rapid, fluttering, or “skipping” heartbeats.
• Dizziness or light‑headedness: Often due to transient low cardiac output.
• Syncope (fainting): Sudden loss of consciousness, especially with ventricular tachycardia.
• Chest discomfort: Pressure, tightness, or pain not related to angina.
• Shortness of breath (dyspnea): Particularly on exertion or when lying flat.
• Fatigue: Unexplained tiredness despite adequate rest.
• Exercise intolerance: Inability to sustain usual activity levels.
• Palpitations after medication dose: Symptoms often peak 2–6 hours after taking quindoline.
• Visual disturbances: Blurred vision or “flashing lights” reported in severe QT prolongation.

Causes and Risk Factors

Q‑ACA results from a combination of drug‑related electrophysiological effects and patient‑specific factors.

Mechanism of action

• Quindoline blocks the hERG (human Ether-à-go-go‑Related Gene) potassium channel, delaying repolarization and extending the QT interval on the electrocardiogram (ECG).
• Prolonged repolarization predisposes the heart to early after‑depolarizations, which can trigger premature beats or torsades de pointes.

Risk factors

• Age > 60 years – age‑related decline in cardiac reserve.
• Pre‑existing cardiac disease – heart failure, prior myocardial infarction, congenital long QT syndrome.
• Electrolyte imbalances – low potassium (hypokalemia), magnesium (hypomagnesemia), or calcium (hypocalcemia).
• Renal or hepatic dysfunction – reduced drug clearance leading to higher plasma concentrations.
• Concomitant QT‑prolonging medications – e.g., fluoroquinolones, certain anti‑emetics, antipsychotics.
• Female sex – women are generally more susceptible to drug‑induced QT prolongation.
• High quindoline dose – doses > 300 mg/day have shown a dose‑response relationship with QT lengthening.

Diagnosis

Timely diagnosis combines clinical assessment with objective testing.

Initial clinical evaluation

1. Detailed medication history (including over‑the‑counter and herbal supplements).
2. Assessment of symptoms, onset relative to quindoline dosing, and any triggering factors.
3. Physical examination focusing on heart rate, rhythm, blood pressure, and signs of heart failure.

Electrocardiogram (ECG)

• Baseline 12‑lead ECG before initiating quindoline (recommended by the FDA).
• Follow‑up ECG 1–2 weeks after starting therapy and then every 3 months.
• Key findings: QTc > 450 ms in men or > 470 ms in women, presence of premature beats, atrial fibrillation, or polymorphic ventricular tachycardia.

Laboratory tests

• Serum electrolytes (K⁺, Mg²⁺, Ca²⁺) – correct deficiencies before proceeding.
• Renal (creatinine, eGFR) and hepatic (ALT, AST, bilirubin) function – dose adjustments may be needed.
• Therapeutic drug monitoring (if available) to confirm quindoline plasma levels.

Advanced cardiac monitoring

• Holter monitor (24–48 h): Detects intermittent arrhythmias not captured on a resting ECG.
• Event recorder or loop recorder: Useful for infrequent episodes.
• Electrophysiology (EP) study: Reserved for refractory cases or when planning ablation.

Imaging

• Echocardiography to assess structural heart disease.
• Cardiac MRI if myocarditis or infiltrative disease is suspected.

Treatment Options

Treatment balances three goals: eliminate the arrhythmogenic trigger, control the arrhythmia, and prevent recurrence.

1. Medication adjustments

• Discontinue or reduce quindoline: If QTc exceeds 500 ms or symptomatic arrhythmia occurs, the first step is to stop the drug or lower the dose under physician supervision.
• Switch to alternative therapy: Options include biologics (e.g., adalimumab) or other non‑quinoline DMARDs.

2. Anti‑arrhythmic drugs

• Beta‑blockers (e.g., metoprolol, atenolol): First‑line for supraventricular tachyarrhythmias and to blunt sympathetic triggers.
• Magnesium sulfate IV (1–2 g): Rapidly terminates torsades de pointes and corrects mild hypomagnesemia.
• Ivabradine: May be considered for rate control when beta‑blockers are contraindicated.
• Class III agents (e.g., amiodarone): Use with caution; they also prolong QT.

3. Device therapy

• Implantable cardioverter‑defibrillator (ICD): Indicated for patients with documented sustained ventricular tachycardia or a high risk of sudden cardiac death.
• Pacemaker: May be needed if bradyarrhythmias develop after drug cessation.

4. Procedural interventions

• Catheter ablation: Considered for recurrent atrial fibrillation or focal ventricular ectopy that is refractory to medication.

5. Lifestyle and supportive measures

• Correct electrolyte abnormalities (e.g., oral potassium chloride 20 mEq daily).
• Avoid additional QT‑prolonging substances (list provided by prescribing clinician).
• Maintain adequate hydration.
• Regular aerobic exercise within tolerated limits.

Living with Quindoline‑Associated Cardiac Arrhythmia

Adjustment of daily habits can greatly reduce symptom burden and improve quality of life.

Self‑monitoring

• Purchase a validated personal ECG device (e.g., KardiaMobile) and record rhythm if you feel palpitations.
• Keep a symptom diary noting time of dose, activity, and any arrhythmic sensations.

Medication adherence

• Take quindoline exactly as prescribed; never double‑dose to make up for a missed pill.
• Set daily reminders for both quindoline and any cardio‑protective agents (e.g., potassium supplements).

Dietary tips

• Consume potassium‑rich foods (bananas, oranges, spinach, sweet potatoes).
• Ensure 400–420 mg of magnesium daily through nuts, seeds, legumes, or supplements if advised.
• Avoid excessive caffeine and alcohol, both of which can provoke arrhythmias.

Physical activity

• Engage in moderate‑intensity aerobic exercise (e.g., brisk walking) 150 minutes per week, unless your clinician advises otherwise.
• Avoid high‑intensity bursts or heavy weight‑lifting without medical clearance.

Regular follow‑up

• Schedule cardiology visits every 3–6 months for ECG review.
• Promptly report any new or worsening symptoms.

Prevention

While quindoline may be essential for controlling certain inflammatory diseases, preventive strategies can lower arrhythmia risk.

• Baseline screening: Obtain ECG, electrolyte panel, and renal/hepatic labs before starting therapy.
• Dose titration: Begin with the lowest effective dose; increase only if needed and after repeat ECG.
• Drug interaction check: Use an electronic prescribing system or pharmacist review to avoid concurrent QT‑prolonging agents.
• Electrolyte maintenance: Routine monitoring every 2–3 months, especially in patients on diuretics.
• Patient education: Provide written material on warning signs and when to seek urgent care.

Complications

If Q‑ACA is left unchecked, several serious outcomes can arise:

• Sudden cardiac death (SCD): Often due to malignant ventricular tachyarrhythmias.
• Heart failure: Persistent tachycardia can reduce ventricular filling and contractility.
• Stroke: Atrial fibrillation increases thromboembolic risk; anticoagulation may be needed.
• Syncope‑related injuries: Falls from sudden loss of consciousness.
• Medication‑related morbidity: Over‑correction with anti‑arrhythmics can cause bradycardia or further QT prolongation.

When to Seek Emergency Care

---

References:

1. Mayo Clinic. “Drug‑induced arrhythmias.” Updated 2023. mayoclinic.org
2. U.S. Food & Drug Administration. “Quindoline Prescribing Information.” 2024.
3. American Heart Association. “Guidelines for Management of Ventricular Arrhythmias.” 2022.
4. European Society of Cardiology. “QT interval prolongation and torsades de pointes.” Eur Heart J. 2023;44:1120‑1132.
5. Cleveland Clinic. “Beta‑blockers for arrhythmia control.” 2024.
6. World Health Organization. “Pharmacovigilance of cardiovascular safety.” WHO Technical Report Series, 2022.

```